Literature DB >> 30561805

Peanut oral immunotherapy increases IgG4 to Ara h 1, 2, and 6 but does not affect IgG4 to other allergens.

Riikka Uotila1, Anna Kaarina Kukkonen1, Dario Greco2,3, Anna Susanna Pelkonen1, Mika Juhani Mäkelä1.   

Abstract

Entities:  

Keywords:  IgG4; Immuno-Solid phase Allergen Chip; cross-reactivity; immunotherapy; peanut allergens

Mesh：

Substances：

Year:  2019        PMID： 30561805     DOI： 10.1111/pai.13012

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  4 in total

Review 1.  The use of microarray and other multiplex technologies in the diagnosis of allergy.

Authors:  Behnam Keshavarz; Thomas A E Platts-Mills; Jeffrey M Wilson
Journal:  Ann Allergy Asthma Immunol       Date:  2021-01-12       Impact factor: 6.248

Review 2.  Recombinant allergens for immunotherapy: state of the art.

Authors:  Yury Zhernov; Mirela Curin; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

Review 3.  B cells and the microbiota: a missing connection in food allergy.

Authors:  Evelyn Campbell; Lauren A Hesser; Cathryn R Nagler
Journal:  Mucosal Immunol       Date:  2020-10-26       Impact factor: 8.701

4.  Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6.

Authors:  Oliver Hemmings; George Du Toit; Suzana Radulovic; Gideon Lack; Alexandra F Santos
Journal:  J Allergy Clin Immunol       Date:  2020-04-13       Impact factor: 10.793
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.